Latest news
Loading news…
Mabtech
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Nacka, Stockholms Lan, Sweden Founded 1986 51-100 employees For Profit
Mabtech supplies a wide range of antibodies to cytokines, immunoglobulins and apolipoproteins.
Mabtech was acquired by EQT in 2024.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
60
Patents
10
16 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 24
- Mobile apps
- 5
- Downloads (30d)
- 5,091
- Patents granted
- 10
- Trademarks
- 16
- Top patent class
- Testing
- IT spend
- $373K
Company Info
- Founded
- 1986
- Employees
- 51-100
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 17
- HQ
- Nacka, Stockholms Lan, Sweden
- Region
- European Union (EU), Nordic Countries, Scandinavia
- Exit date
- Jan 9, 2024
Signals & Scores
- Heat score
- Medium
- Growth score
- Low
- Trend (7d)
- -0.1
- Trend (30d)
- 0
- Trend (90d)
- -1
Key People at Mabtech
Founder, CEO and Partner
60
professional contacts at Mabtech
Contact execs at Mabtech →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Mabtech
Loading news…
FAQs about Mabtech
People who checked this page also checked these
Browse the full Acquirezy directory.